Technical Analysis for CLSN - Celsion Corporation

Grade Last Price % Change Price Change
grade F 1.2337 -11.24% -0.16
CLSN closed up 28.69 percent on Thursday, November 14, 2019, on 3.05 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 15

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLSN trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -11.24%
Volume Surge Other -11.24%
Wide Range Bar Range Expansion -11.24%
Lower Bollinger Band Walk Weakness -11.24%
Wide Bands Range Expansion -11.24%
Gapped Up Strength -11.24%
Oversold Stochastic Weakness -11.24%
New 52 Week Closing Low Bearish 14.22%
Volume Surge Other 14.22%
Lower Bollinger Band Walk Weakness 14.22%

Older signals for CLSN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.
Medicine Cancer Clinical Medicine Cancers Chemotherapy Ultrasound Drug Development Antineoplastic Drugs Hepatology Hepatocellular Carcinoma High Intensity Focused Ultrasound Anthracyclines Doxorubicin Teratogens
Is CLSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.63
52 Week Low 1.05
Average Volume 160,079
200-Day Moving Average 1.9149
50-Day Moving Average 1.6361
20-Day Moving Average 1.5503
10-Day Moving Average 1.395
Average True Range 0.1543
ADX 42.19
+DI 21.3119
-DI 33.5509
Chandelier Exit (Long, 3 ATRs ) 1.3171
Chandelier Exit (Short, 3 ATRs ) 1.5129
Upper Bollinger Band 1.9614
Lower Bollinger Band 1.1392
Percent B (%b) 0.31
BandWidth 53.034896
MACD Line -0.1195
MACD Signal Line -0.0795
MACD Histogram -0.04
Fundamentals Value
Market Cap 11.61 Million
Num Shares 8.35 Million
EPS -5.58
Price-to-Earnings (P/E) Ratio -0.25
Price-to-Sales 47.77
Price-to-Book 2.54
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.97
Resistance 3 (R3) 1.95 1.75 1.87
Resistance 2 (R2) 1.75 1.60 1.75 1.84
Resistance 1 (R1) 1.57 1.51 1.66 1.58 1.81
Pivot Point 1.36 1.36 1.41 1.37 1.36
Support 1 (S1) 1.18 1.21 1.27 1.20 0.97
Support 2 (S2) 0.98 1.12 0.98 0.94
Support 3 (S3) 0.80 0.98 0.91
Support 4 (S4) 0.81